Phillip Thienger

The paper identifies Aurora kinase A as a synthetic lethal target in FANCA-deficient cancers and shows AURKA inhibition induces chromosomal instability and G2/M arrest in these cells.

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

This study shows that targeting the minor spliceosome, specifically U6atac snRNA, disrupts DNA repair and overcomes therapy resistance in prostate and breast cancers.